Malcolm Weir, Sosei vice chairman

Glax­o­SmithK­line joins So­sei's who's-who list of clients with glob­al li­cens­ing pact for IBD small mol­e­cules

Big drug­mak­ers are on the hunt for nov­el ther­a­peu­tics in a range of ul­tra-com­pet­i­tive ther­a­peu­tic ar­eas. Japan’s So­sei Hep­tares has emerged in re­cent years as a sought-af­ter part­ner for Big Phar­mas seek­ing nov­el neu­ro can­di­dates — but now Glax­o­SmithK­line wants to try the pre­clin­i­cal R&D ex­pert’s work in in­flam­ma­to­ry bow­el dis­ease.

GSK has tapped So­sei Hep­tares for dis­cov­ery work tar­get­ing IBD and oth­er gas­troin­testi­nal im­mune dis­or­ders with small-mol­e­cule ag­o­nists for GPR35, an or­phan G pro­tein-cou­pled re­cep­tor (GPCR) with a ge­net­ic link to those con­di­tions, the com­pa­nies said Sun­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.